Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 17, 2016. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them (PCAs). The filing does not contain general business updates or operational reports.
Key Financial Metrics
The filing does not provide corporate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to specific share transactions:
- Instrument: American Depositary Shares (ADSs), ISIN: US37733W1053.
- Transaction Price: $42.39 per ADS.
- Total Volume Reported: Approximately 9,048 ADSs across five individuals.
Material Changes
No material changes to the company's financial position or operations are reported. The filing details an increase in notional interest in ADSs for five individuals. These increases resulted from the re-investment of dividends paid on October 13, 2016, under the Company's 2009 Performance Share Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or unusual items. It is strictly a regulatory disclosure of share plan activity.
Investor Verification Points
- Verify the dividend re-investment mechanism for the 2009 Performance Share Plan to confirm the nature of the "notional interest" increase.
- Confirm the market price of GSK ADSs on October 13, 2016, to validate the reported transaction price of $42.39.
- Review the specific roles of the notified individuals (e.g., Chairman of Global Vaccines, CEO of Consumer Healthcare) to assess potential insider sentiment, though these were automated dividend reinvestments.